Keros Therapeutics (KROS) Misses Q1 EPS by 18c

Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of ($1.21), $0.18 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $370 thousand versus the consensus estimate of $1.69 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
• Lazard Global Total Return fund declares $0.1534 monthly distribution